Novavax Inc (WBO:NVAX)
€ 9.276 -0.09 (-0.96%) Market Cap: 1.49 Bil Enterprise Value: 734.28 Mil PE Ratio: 0 PB Ratio: 0 GF Score: 47/100

Novavax, Inc. - Special Call Transcript

Jan 28, 2021 / 09:30PM GMT
Operator

Ladies and gentlemen, thank you for standing by, and welcome to the Novavax provides update conference call. (Operator Instructions) Please be advised that today's conference is being recorded. (Operator Instructions)

I would now like to hand the conference over to your speaker today, Silvia Taylor. Please go ahead.

Silvia Taylor
Novavax, Inc. - SVP of IR & Corporate Affairs

Thank you, and good afternoon, everyone. Thank you for joining today's call and webcast. Earlier today, we issued a press release announcing top line data results from our recent Phase III trial in the U.K. and Phase IIb trial in South Africa. That press release is available on our website at novavax.com as our slides we will be using during this afternoon's call. An audio archive of this call will also be available on our website later today.

Before we begin, I need to remind you that we will be making forward-looking statements during this teleconference that could include financial, clinical or commercial projections. Statements relating to future financial or

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot